RIGL - Rigel Pharmaceuticals, Inc.
| Previous Close | 1.9200 |
| Open | 1.9200 |
| Bid | 1.9400 x 4000 |
| Ask | 2.3500 x 21500 |
| Day's Range | 1.8700 - 1.9700 |
| 52 Week Range | 1.8700 - 3.6500 |
| Volume | 1,582,773 |
| Avg. Volume | 1,230,269 |
| Market Cap | 324.354M |
| Beta (3Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3850 |
| Earnings Date | Aug 2, 2018 - Aug 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.33 |
- Simply Wall St.
Who Has Been Buying Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
- Thomson Reuters StreetEvents
Edited Transcript of RIGL earnings conference call or presentation 6-Aug-19 8:30pm GMT
Q2 2019 Rigel Pharmaceuticals Inc Earnings Call
Motley FoolRigel Pharmaceuticals Inc (RIGL) Q2 2019 Earnings Call Transcript
RIGL earnings call for the period ending June 30, 2019.
- Zacks
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 14.29% and 12.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update
TAVALISSE® net product sales increased 26% quarter over quarter to $10.2 million First patients enrolled in Phase 3 pivotal trial of TAVALISSE in warm autoimmune hemolytic anemia (AIHA) Conference call ...
- Zacks
What's in the Cards for Bausch Health (BHC) in Q2 Earnings?
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
- Zacks
Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.
- PR Newswire
Rigel Announces Conference Call and Webcast to Report Second Quarter 2019 Financial Results
SOUTH SAN FRANCISCO , July 30, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2019 financial results after market close on Tuesday, ...
- Simply Wall St.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Are Analysts Optimistic?
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL): Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the...
- Zacks
Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Rigel Pharmaceuticals, Inc. (RIGL) has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks
Dova Receives Approval for Doptelet in Europe, Stock Up
Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.
- Insider Monkey
Here’s What Hedge Funds Think About Rigel Pharmaceuticals, Inc. (RIGL)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- PR Newswire
Rigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA)
SOUTH SAN FRANCISCO , June 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two posters ...
- Motley Fool
Is Rigel Pharmaceuticals a Buy?
The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?
- Thomson Reuters StreetEvents
Edited Transcript of RIGL earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Rigel Pharmaceuticals Inc Earnings Call
- PR Newswire
Rigel to Present at Jefferies 2019 Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , May 31, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, is scheduled to present ...
- Zacks
Rigel Initiates Enrollment in Pivotal Blood Disorder Study
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
- PR Newswire
Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia
SOUTH SAN FRANCISCO, Calif., May 16, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL), today announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium hexahydrate (fostamatinib) in warm antibody autoimmune hemolytic anemia (AIHA). "Enrolling the first patient in our Phase 3 clinical trial of fostamatinib in warm AIHA is an important milestone in our efforts to develop the first FDA-approved therapy for this disease," stated Raul Rodriguez, president and CEO.
Motley FoolRigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript
RIGL earnings call for the period ending March 31, 2019.
- Zacks
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Tops Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 5.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Rigel: 1Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 11 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by ...
- PR Newswire
Rigel Announces First Quarter 2019 Financial Results and Provides Company Update
TAVALISSE® net product sales of $8.1 million on 1,019 bottles, a 10% increase quarter-over-quarter Total revenues of $12.6 million , including $4.6 million from collaborations Opened clinical trial sites ...
- PR Newswire
Rigel Announces Conference Call and Webcast to Report First Quarter 2019 Financial Results and Company Update
SOUTH SAN FRANCISCO, Calif. , April 30, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2019 financial results after market close on ...
- Simply Wall St.
If You Had Bought Rigel Pharmaceuticals (NASDAQ:RIGL) Stock A Year Ago, You'd Be Sitting On A 40% Loss, Today
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders should be happy to see the share price up 16% in the last quarter. But that is minimal compensation for the share price under-performance over the last year. After all...
